A roundup of the major presentations on HIV science at the international conference held July 22 to 28 outlines many exciting developments.

Among young men on Truvada as PrEP, bone loss stabilizes after first year and reverses after stopping.

Just 4 percent of children born to HIV-positive mothers contract the virus by 18 months of age.

The cure rate for Gilead’s new treatment is comparable to what has been seen in people who have only hep C.

A new study examines factors that predicted which black men who have sex with men (MSM) would better stick with the daily Truvada regimen.

See what happens when people affected by HIV gain access to treatment.

But will there be enough money to keep pushing the dial?

The Phase IIb/III HVTN 702 trial will begin enrollment in southern Africa in the fall.

The final results of the HPTN 052 study of mixed-HIV-status, opposite-sex partners are in.

Constantly adapting the way that the response tries to reach young people is key.